Adherium iCARE Respiratory Program Results deliver 67% hospitalisation reduction and $12,943 annual savings per patient
Adherium Limited (ASX: ADR) has announced preliminary Adherium iCARE Respiratory Program Results demonstrating a 67% reduction in hospitalisations and 46% reduction in total cost of care among approximately 850 COPD and asthma patients. The real-world study findings, presented at the Big Sky Pulmonary Conference in Montana on 5 March 2026, showed average annual savings of $12,943 per patient enrolled through Intermountain Health between March 2024 and August 2025.
The iCARE study is a large-scale, real-world respiratory care programme designed to evaluate how connected inhaler technology and remote monitoring can improve outcomes for patients with chronic respiratory diseases. Additional results are expected to be presented at the American Thoracic Society conference from 15-20 May 2026.
Study investigator Kim Bennion of Intermountain Health presented the analysis, which reported inpatient encounters reducing from 3.27 to 0.93 per patient per year. For those hospitalised, length of stay decreased by 57%, whilst total cost of care fell from $28,235 to $15,202.
| Metric | Before iCARE | After iCARE | Reduction |
|---|---|---|---|
| Hospitalisations (per patient/year) | 3.27 | 0.93 | 67% |
| Length of stay (hospitalised patients) | Baseline | Post-intervention | 57% |
| Total cost of care | $28,235 | $15,202 | 46% |
| Average annual savings per patient | — | $12,943 | |
These outcomes provide evidence supporting commercial viability for value-based care contracts with US insurers, demonstrating quantifiable cost reductions alongside improved patient health metrics.
When big ASX news breaks, our subscribers know first
How remote respiratory monitoring works and why it matters
The iCARE programme combines connected respiratory monitoring enabled by Adherium’s Hailie Smartinhaler technology with AI-driven behavioural engagement to support adherence and earlier intervention outside the clinic. Smartinhaler devices attach to commonly used inhalers to capture and transmit inhalation event data, enabling patients and care teams to understand medication-use patterns.
The FDA-cleared Hailie platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The technology enables healthcare providers to intervene earlier and monitor patients between clinic visits, shifting care delivery from reactive to proactive respiratory management.
The platform’s three core components operate as follows:
- Hailie Smartinhaler sensors attach to standard inhalers and transmit usage data to care teams
- AI-driven behavioural engagement tools support patient adherence through personalised interventions
- Remote monitoring dashboard enables clinicians to track medication patterns and identify patients requiring intervention
This model underpins the value proposition for value-based reimbursement structures increasingly sought by US healthcare systems and insurers, where providers are compensated based on patient outcomes rather than service volume.
Patient adherence and engagement metrics validate platform stickiness
The iCARE study demonstrated typical adherence of nearly two-thirds among participants, with nearly 4 in 10 patients achieving greater than 80% adherence. This 80% threshold is linked to meaningfully fewer respiratory attacks and hospital admissions, representing a clinically significant benchmark for chronic respiratory disease management.
Platform persistence reached 54% among active users over 14 months, indicating sustained engagement even among older, higher-risk patients. More than 90% of the approximately 850 enrolled patients remain active participants in the programme, according to preliminary analysis released to the ASX on 15 September 2025.
Key adherence and engagement findings include:
- ~66% typical adherence rate across the patient population
- ~40% of patients achieved adherence levels exceeding 80%, the clinical threshold associated with reduced respiratory attacks
- 54% platform persistence over 14 months, demonstrating long-term user engagement
- Over 90% of enrolled patients remain active programme participants
Sustained patient engagement is essential for demonstrating long-term value to insurers under value-based care models. High persistence rates reduce the commercial risk associated with remote patient monitoring contracts, as payers require evidence that technology adoption translates into durable behaviour change and ongoing cost containment.
CEO commentary on commercial implications
Dawn Bitz, CEO, Adherium Limited
“These outstanding early results underscore the impact that remote patient monitoring delivered through iCARE can have on patients’ lives, the healthcare system, and healthcare costs. We are very pleased with how the study is progressing and look forward to seeing more data presented at the American Thoracic Society 2026 International Conference from 15-20 May.”
The statement positions the preliminary findings as validation of the platform’s commercial readiness, particularly as the company pursues value-based contracts with US healthcare systems.
The next major ASX story will hit our subscribers first
Programme scale and upcoming catalysts position Adherium for US insurer contracts
The iCARE study includes deployment of 4,000 Hailie Smartinhalers supporting up to 2,500 COPD and asthma patients across five Intermountain Health facilities over two years. This scale demonstrates the operational feasibility of the remote monitoring model across multiple sites, a critical consideration for healthcare systems evaluating platform adoption.
Additional analysis is planned for presentation at the American Thoracic Society conference from 15-20 May 2026, including:
- Outcomes segmented by disease category (COPD versus asthma)
- Patient severity stratification analysis
- Payor type comparison (commercial insurance versus Medicare/Medicaid)
- Environmental and socioeconomic factor analysis
The expanded dataset will provide insurers and healthcare systems with granular evidence to support contracting decisions. Together with growth in Adherium’s Remote Patient Monitoring channel, positive iCARE results position the company to negotiate new value-based contracts and expanded reimbursement arrangements.
Healthcare systems and insurers are actively seeking technologies that improve outcomes whilst reducing costs. The iCARE dataset provides the real-world evidence base required to demonstrate return on investment under risk-sharing arrangements where providers are financially accountable for patient outcomes.
Investment thesis summary
The Adherium iCARE Respiratory Program Results represent a significant commercial catalyst for the company’s US market strategy. Real-world proof of $12,943 annual cost savings per patient, combined with 67% hospitalisation reduction, positions Adherium to capture revenue from the expanding US value-based care market.
Key investment takeaways include:
- Proven health economics: 46% reduction in total cost of care provides quantifiable value proposition for US insurers
- Clinical validation: 67% hospitalisation reduction and 57% shorter hospital stays demonstrate meaningful outcome improvement
- Market positioning: Global leader in connected respiratory devices with over 180,000 units sold globally
- Near-term catalyst: American Thoracic Society conference (15-20 May 2026) will provide expanded dataset including disease-specific and payor-type analysis
- Commercial pipeline: Growing Remote Patient Monitoring channel combined with iCARE results creates foundation for new value-based contracts
The company’s FDA-cleared Hailie platform provides the regulatory and clinical foundation required to penetrate the US remote patient monitoring market, where reimbursement structures increasingly favour technologies demonstrating cost reduction alongside improved patient outcomes.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with expert analysis. Click the “Free Alerts” button at Big News Blast to get real-time alerts the moment market-moving announcements drop, so you’re always ahead of the curve.